{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:05:32Z","timestamp":1781625932020,"version":"3.54.5"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ruby&Rose","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      CanRisk is a risk prediction tool used to estimate tubo-ovarian cancer risk. It is increasingly being used in clinical practice. However, guidelines regarding the use of the CanRisk tool in clinical practice are lacking. Therefore, we aim to identify recommendations for the use of CanRisk in clinical practice. First, we organized separate focus group interviews with clinical genetic healthcare providers, gynecologic\u2013oncology healthcare providers, patients, and patient advocates to identify relevant themes and subthemes regarding the use of CanRisk. Subsequently, we followed a Research ANd Development-modified Delphi-based approach using a questionnaire round consisting of statements based on previously identified themes, followed by a consensus meeting. Statements with consensus were transferred into recommendations and sent for approval to all participants who completed the questionnaire. We identified 44 statements based on the focus group meetings. Consensus was reached on 19 statements, of which 17 were transferred to recommendations. They concerned CanRisk itself (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2005=\u20053), counseling (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2005=\u20054), indications for the use of CanRisk (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2005=\u20052), data entry into CanRisk (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2005=\u20053), decisions regarding risk-reducing surgery and CanRisk (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2005=\u20052), education (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2005=\u20051), and collaboration regarding CanRisk (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2005=\u20054). Recommendations included that clinical geneticists should use CanRisk and communicate results to the gynecologic oncologist. Furthermore, the CanRisk result should not be used as an absolute threshold for risk-reducing surgery eligibility. This research identified recommendations for the use of CanRisk in clinical practice to standardize and optimize tubo-ovarian cancer prevention. CanRisk was seen as a valuable addition to healthcare that should be used in a uniform manner.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cej.0000000000001024","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:01:37Z","timestamp":1781622097000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Recommendations for the use of CanRisk for tubo-ovarian cancer risk estimation: a focus group and Research ANd Development-modified Delphi-based study"],"prefix":"10.1097","author":[{"given":"Tamar A.","family":"Gootzen","sequence":"first","affiliation":[{"name":"Department of Gynecology and Obstetrics, Radboudumc"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolijn","family":"Schauwaert","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Radboudumc"},{"name":"Science Department IQ Health Radboudumc"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda P.","family":"Steenbeek","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Radboudumc"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"van Altena","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Radboudumc"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne A.","family":"de Hullu","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Radboudumc"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Marleen","family":"Kets","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics, Radboudumc, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosella P.M.G.","family":"Hermens","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics, Radboudumc, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Consortium CanRisk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"R1-20260616","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.","volume":"30","author":"Alsop","year":"2012","journal-title":"J Clin Oncol"},{"key":"R2-20260616","doi-asserted-by":"crossref","first-page":"e0229999","DOI":"10.1371\/journal.pone.0229999","article-title":"Evaluating clinician acceptability of the prototype CanRisk tool for predicting risk of breast and ovarian cancer: a multi-methods study.","volume":"15","author":"Archer","year":"2020","journal-title":"PLoS One"},{"key":"R3-20260616","doi-asserted-by":"crossref","first-page":"e586","DOI":"10.3399\/BJGP.2022.0643","article-title":"Exploring the barriers to and facilitators of implementing CanRisk in primary care: a qualitative thematic framework analysis.","volume":"73","author":"Archer","year":"2023","journal-title":"Br J Gen Pract"},{"key":"R5-20260616","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1158\/1055-9965.EPI-20-1319","article-title":"CanRisk tool-a web interface for the prediction of breast and ovarian cancer risk and the likelihood of carrying genetic pathogenic variants.","volume":"30","author":"Carver","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R6-20260616","doi-asserted-by":"crossref","first-page":"pkaa029","DOI":"10.1093\/jncics\/pkaa029","article-title":"Penetrance of breast and ovarian cancer in women who carry a BRCA1\/2 mutation and do not use risk-reducing salpingo-oophorectomy: an updated meta-analysis.","volume":"4","author":"Chen","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"R7-20260616","doi-asserted-by":"crossref","first-page":"a1655","DOI":"10.1136\/bmj.a1655","article-title":"Developing and evaluating complex interventions: the new Medical Research Council guidance.","volume":"337","author":"Craig","year":"2008","journal-title":"Bmj"},{"key":"R8-20260616","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/jmedgenet-2012-101415","article-title":"Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1\/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium.","volume":"50","author":"Fischer","year":"2013","journal-title":"J Med Genet"},{"key":"R10-20260616","article-title":"De arbeidsmarkt van de Nederlandse huisartsenzorg in 2024: toelichting en samenvatting van het onderzoek onder huisartsenpraktijken in 2024, met landelijke uitkomsten, trends en regionale factsheets.","author":"Flinterman","year":"2025","journal-title":"Nivel"},{"key":"R11-20260616","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1748-5908-8-35","article-title":"A checklist for identifying determinants of practice: a systematic review and synthesis of frameworks and taxonomies of factors that prevent or enable improvements in healthcare professional practice.","volume":"8","author":"Flottorp","year":"2013","journal-title":"Implement Sci"},{"key":"R12-20260616","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1136\/jmg-2022-108898","article-title":"UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2.","volume":"60","author":"Hanson","year":"2023","journal-title":"J Med Genet"},{"key":"R13-20260616","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/jmedgenet-2015-103077","article-title":"A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects.","volume":"52","author":"Jervis","year":"2015","journal-title":"J Med Genet"},{"key":"R14-20260616","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"R16-20260616","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1136\/jmedgenet-2022-108471","article-title":"Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1 updates to tumour pathology and cancer incidence.","volume":"59","author":"Lee","year":"2022","journal-title":"J Med Genet"},{"key":"R17-20260616","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer.","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"key":"R18-20260616","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/S0140-6736(21)00731-5","article-title":"Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.","volume":"397","author":"Menon","year":"2021","journal-title":"Lancet"},{"key":"R19-20260616","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(23)00335-2","article-title":"Tumour stage, treatment, and survival of women with high-grade serous tubo-ovarian cancer in UKCTOCS: an exploratory analysis of a randomised controlled trial.","volume":"24","author":"Menon","year":"2023","journal-title":"Lancet Oncol"},{"key":"R20-20260616","doi-asserted-by":"crossref","first-page":"h1258","DOI":"10.1136\/bmj.h1258","article-title":"Process evaluation of complex interventions: Medical Research Council guidance.","volume":"350","author":"Moore","year":"2015","journal-title":"Bmj"},{"key":"R21-20260616","doi-asserted-by":"crossref","first-page":"101230","DOI":"10.1016\/j.gim.2024.101230","article-title":"Extended panel testing in ovarian cancer reveals BRIP1 as the third most important predisposition gene.","volume":"26","author":"Morgan","year":"2024","journal-title":"Genet Med"},{"key":"R22-20260616","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1001\/jamacardio.2016.2415","article-title":"Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis.","volume":"1","author":"Muka","year":"2016","journal-title":"JAMA Cardiol"},{"key":"R25-20260616","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.3390\/cancers12103046","article-title":"Rare germline genetic variants and the risks of epithelial ovarian cancer.","volume":"12","author":"Pavanello","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R26-20260616","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1093\/jnci\/djae335","article-title":"Evaluating the performance of the Breast and Ovarian Analysis of Disease Incidence Algorithm model in predicting 10-year breast cancer risks in UK Biobank.","volume":"117","author":"Petitjean","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"R28-20260616","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1016\/j.ejca.2004.09.008","article-title":"BRCA2, but not BRCA1, mutations account for familial ovarian cancer in Iceland: a population-based study.","volume":"40","author":"Rafnar","year":"2004","journal-title":"Eur J Cancer"},{"key":"R29-20260616","doi-asserted-by":"crossref","first-page":"djv214","DOI":"10.1093\/jnci\/djv214","article-title":"Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer.","volume":"107","author":"Ramus","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"R30-20260616","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.","volume":"101","author":"Rebbeck","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"R31-20260616","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1212\/01.wnl.0000276984.19542.e6","article-title":"Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause.","volume":"69","author":"Rocca","year":"2007","journal-title":"Neurology"},{"key":"R32-20260616","doi-asserted-by":"crossref","first-page":"e2238663","DOI":"10.1001\/jamanetworkopen.2022.38663","article-title":"Association of premenopausal bilateral oophorectomy with parkinsonism and parkinson disease.","volume":"5","author":"Rocca","year":"2022","journal-title":"JAMA Netw Open"},{"key":"R33-20260616","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/sj.ejhg.5200652","article-title":"BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients.","volume":"9","author":"Sarantaus","year":"2001","journal-title":"Eur J Hum Genet"},{"key":"R34-20260616","doi-asserted-by":"crossref","first-page":"e32829","DOI":"10.1097\/MD.0000000000032829","article-title":"Use of Delphi in health sciences research: a narrative review.","volume":"102","author":"Shang","year":"2023","journal-title":"Medicine (Baltim)"},{"key":"R35-20260616","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1001\/jamaoncol.2021.1590","article-title":"Association of salpingectomy with delayed oophorectomy versus salpingo-oophorectomy with quality of life in BRCA1\/2 pathogenic variant carriers: a nonrandomized controlled trial.","volume":"7","author":"Steenbeek","year":"2021","journal-title":"JAMA Oncol"},{"key":"R36-20260616","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1038\/s41416-024-02733-4","article-title":"Joint ABS-UKCGG-CanGene-CanVar consensus regarding the use of CanRisk in clinical practice.","volume":"130","author":"Tsoulaki","year":"2024","journal-title":"Br J Cancer"},{"key":"R37-20260616","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/1471-0528.18075","article-title":"Salpingectomy with delayed oophorectomy versus salpingo-oophorectomy in BRCA1\/2 carriers: three-year outcomes of a prospective preference trial.","volume":"132","author":"Van Bommel","year":"2025","journal-title":"Bjog"},{"key":"R38-20260616","doi-asserted-by":"crossref","first-page":"6117","DOI":"10.3390\/cancers14246117","article-title":"Cost-effectiveness of risk-reducing surgery for breast and ovarian cancer prevention: a systematic review.","volume":"14","author":"Wei","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R39-20260616","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ygyno.2023.04.029","article-title":"The most efficient and effective BRCA1\/2 testing strategy in epithelial ovarian cancer: tumor-first or germline-first?.","volume":"174","author":"Witjes","year":"2023","journal-title":"Gynecol Oncol"},{"key":"R40-20260616","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1136\/jmg-2022-108806","article-title":"Prospective validation of the BOADICEA multifactorial breast cancer risk prediction model in a large prospective cohort study.","volume":"59","author":"Yang","year":"2022","journal-title":"J Med Genet"},{"key":"R41-20260616","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1136\/jmg-2024-109943","article-title":"Validation of the BOADICEA model in a prospective cohort of BRCA1\/2 pathogenic variant carriers.","volume":"61","author":"Yang","year":"2024","journal-title":"J Med Genet"}],"container-title":["European Journal of Cancer Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000001024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:01:40Z","timestamp":1781622100000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000001024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":35,"URL":"https:\/\/doi.org\/10.1097\/cej.0000000000001024","relation":{},"ISSN":["0959-8278","1473-5709"],"issn-type":[{"value":"0959-8278","type":"print"},{"value":"1473-5709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"2026-03-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}